Related Experiment Video
Updated: May 15, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
[Vaccination against human papillomavirus infections. Indications, coverage and perspectives]
Léa Vimpere1, Ania Wisniak2, Matteo Reymond1
1Unité VIH, Service des maladies infectieuses, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
Human papillomavirus (HPV) infections represent a major public health concern due to their role in the development of anogenital and oropharyngeal cancers. Vaccination against oncogenic HPVs has demonstrated high efficacy in preventing associated (pre)cancerous lesions. In Switzerland, HPV vaccination is recommended and reimbursed for individuals aged 11 to 26 years. The development of targeted information campaigns is essential to improve vaccination coverage among boys and vulnerable populations. New approaches, such as single-dose vaccination, targeted vaccination beyond the age of 26, and prophylactic vaccination, appear to be promising strategies for optimizing prevention.
More Related Videos
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Tumor Immunotherapy
Preventive Healthcare Services
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

